TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21840137
Drug: Triweekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triweekly cisplatin 75 mg/m(2) every 3 weeks, three cycles
Study: 15608761
Drug: Curamed colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curamed colostrum tablets
Study: 3541824
Drug: Metoprolol, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 150 mg daily
Study: 3541824
Drug: Atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 100 mg daily
Study: 3541824
Drug: Drug-free control
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free control day
Study: 24052631
Drug: Oral paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral paricalcitol (1 μg one time daily)
Study: 20816187
Drug: LABA monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA monotherapy
Study: 15851891
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg lidocaine infused over 30 min
Study: 10562779
Drug: Nebulized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized lidocaine (4% solution, 4 ml)
Study: 475943
Drug: Dexamphetamine 10
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine 10 mg
Study: 9337378
Drug: Bupropion 100
Normalized name: buPROPion 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 100 mg
Study: 6405773
Drug: Bupropion 200
Normalized name: buPROPion 200 mg/12 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 200 mg
Study: 3397523
Drug: Nomifensine 100
Normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine 100 mg
Study: 30428122
Drug: Transcutaneous supraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous supraorbital neurostimulation (tSNS) for 20 minutes daily for 3 months
Study: 25555562
Drug: Polydextrose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (15 g)
Study: 23303421
Drug: Continuation ECT
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation ECT with pharmacotherapy
Study: 19665538
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg body weight of freeze dried Momordica charantia (MC50)
Study: 19665538
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg body weight of freeze dried Momordica charantia (MC100)
Study: 12784050
Drug: Polymyxin B-immobilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-immobilized fiber (PMX) treatment
Study: 26383592
Drug: Topical 8-methoxypsoralen
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 8-methoxypsoralen (8-MOP) 2.6 mg L(-1)
Study: 24524806
Drug: Lixisenatide 5
Normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 5 and 10 µg single dose; 5 to 30 µg once (QD) or twice daily (BID) for 5-6 weeks
Study: 22380715
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered within one hour of injury
Study: 22380715
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered within three hours of injury
Study: 17378785
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of propofol 10 mg/ml
Study: 17378785
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride 9.0 mg/ml
Study: 12094125
Drug: CHO/PRO (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO/PRO (8.4 Mj x day(‐1) or 2010 kcal, 356 g carbohydrate, 106 g protein)
Study: 12094125
Drug: CHO (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (isocaloric carbohydrate supplement)
Study: 10221439
Drug: BUD 1600
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD 1600 microg inhaled into the lungs
Study: 10221439
Drug: BUD (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD (200 and 800 microg) and FP (200 and 800 microg) administered in the nose
Study: 10221439
Drug: FP (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP (1500 microg) inhaled into the lungs
Study: 2331054
Drug: 0.005 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005 mg/kg fentanyl prior to intubation
Study: 31409556
Drug: Colchicine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.5 mg PO)
Study: 23722418
Drug: Nicorandil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (2 mg)
Study: 23722418
Drug: Nitroglycerin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (250 μg)
Study: 21479243
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity promotion by general practitioners (repeat prescription subgroup)
Study: 19451428
Drug: Melphalan and
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan and prednisone plus thalidomide (100 mg/d for 72 weeks)
Study: 16939514
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (CsA)
Study: 10202164
Drug: Pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin (45 Gy of radiation to the pelvis plus two cycles of chemotherapy).
Study: 2161435
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy with lisinopril (30-45 days)
Study: 16840744
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 or 5 mg/kg)
Study: 26861051
Drug: Mesalamine granules
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine granules (MG)
Study: 18390083
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (intramuscular)
Study: 12505865
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day for 1 month)
Study: 2142292
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline solution
Study: 28936
Drug: Etilefrine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine (0.25 mg/min)
Study: 3297521
Drug: No CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CPAP treatment
Study: 30665439
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1000 mg)
Study: 25631258
Drug: 2% PQ10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% PQ10 gel
Study: 21724197
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (high dose)
Study: 15180757
Drug: omalizumab (>/=
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab (>/= 0.016 mg/kg/IgE [IU/ml] per 4 weeks)
Study: 7640969
Drug: Functional Standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Standing Test (FST) administered by two testers
Study: 7640969
Drug: Functional Standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Standing Test (FST) administered to adolescents with SCI
Study: 7640969
Drug: Functional Standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Standing Test (FST) administered to able-bodied young adults
Study: 23946328
Drug: CHOP-R (doxorubicin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-R (doxorubicin-based therapy)
Study: 15181095
Drug: Dihydrotestosterone (DHT)
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Stanolone acetate (DB13951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrotestosterone (DHT) - daily transdermal, n = 17, for 3 months
Study: 15181095
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human chorionic gonadotropin (rhCG) - subcutaneous, two injections weekly, n = 20, for 3 months
Study: 8302148
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous labetalol (1.0‐1.5 mg/Kg, repeated bolus of 10 mg/bolus)
Study: 24237300
Drug: Interferon-alpha lozenge
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha lozenge 1500 IU/day
Study: 22398262
Drug: Adding low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding low level laser therapy (LLLT) to ultrasound (US) and exercise
Study: 10361382
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg in an i.v. bolus injection)
Study: 7732443
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group managed without radiocontrast material, received a suppository on the third day
Study: 7037504
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (betamethasone valerate or clobetasone butyrate)
Study: 30302838
Drug: Knowledge to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge to advise on medications
Study: 6711601
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid therapy
Study: 27812547
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide
Study: 7708638
Drug: Aspirin test
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin test
Study: 30395011
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Study: 30395011
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of quadrivalent, split‐virion, inactivated influenza vaccine (IIV4)
Study: 30395011
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of IIV4
Study: 16996784
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of risk factors in oral cancer; 100% identified tobacco as a risk factor.
Study: 16996784
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of risk factors in oral cancer; 90% identified alcohol as a risk factor.
Study: 16996784
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of risk factors in oral cancer; 50.7% identified sun exposure with labial cancer.
Study: 16996784
Drug: Advice on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice on prevention of oral cancer; 51.4% routinely gave advice to patients.
Study: 16996784
Drug: Self-assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessment of training; 57.1% did not consider themselves sufficiently trained to discover suspected oral cancer lesions.
Study: 16996784
Drug: Perception of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perception of academic training; 84.3% recognized insufficient academic training on early diagnosis and prevention of oral cancer.
Study: 2701817
Drug: Intraoperative portal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative portal chemotherapy without blood transfusion
Study: 28719280
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) - one round
Study: 28719280
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) - two rounds
Study: 23503379
Drug: Genetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic therapy combined with reconstructive vascular operations in 35 patients.
Study: 23503379
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (control group) in 60 patients.
Study: 18823290
Drug: JNJ-38488502 (0.42
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38488502 (0.42 mg kg(‐1) i.v. infusion)
Study: 15284373
Drug: 1.20 g
Normalized name: OCTINOXATE 1.5 g in 30 g / TITANIUM DIOXIDE 1.20 g in 30 g TOPICAL LOTION [Sun Essential]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.20 g protein/(kg. d) for 2 wk (HPro)
Study: 15284373
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g protein/(kg. d) for 1 wk and then 0.50 g protein/(kg. d) for a 2nd week (IPro)
Study: 28314555
Drug: Levobupivacain injection
Normalized name: levobupivacaine Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacain injection (L group)
Study: 28314555
Drug: Levobupivacain and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacain and magnesium sulfate injection (LM group)
Study: 26165259
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion through an On Q continuous infusion pump (On Q group)
Study: 23257347
Drug: Bimosiamose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimosiamose (10 mg) inhaled twice daily for 28 days
Study: 30734406
Drug: Family-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based treatment (FBT-BN)
Study: 15886245
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg, twice daily)
Study: 10081536
Drug: Glucose 10%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 10%, 3 ml.kg‐1.h‐1 (300 mg.kg‐1.h‐1)
Study: 7593729
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg three times daily
Study: 30591028
Drug: Olaratumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaratumab (20 mg/kg, IV infusion) plus liposomal doxorubicin (40 mg/m2, IV infusion) every 4 weeks
Study: 24104699
Drug: Inactivity control
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivity control group (normal daily activities)
Study: 21094362
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus a β blocker (Group C)
Study: 21094362
Drug: β blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blocker alone (Group D)
Study: 17004410
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) at 1.75 atm abs (n=57)
Study: 10907671
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (600 ml/day) in healthy volunteers
Study: 27207107
Drug: Gemcitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m² i.v., days 1 and 8) and cisplatin (75 mg/m² i.v., day 1) alone
Study: 22527887
Drug: Pasireotide 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 50 μg sc qd for 14 days
Study: 22527887
Drug: Pasireotide 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 200 μg sc qd for 14 days
Study: 22527887
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc qd for 14 days
Study: 16299240
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral aminopterin, 2 mg/m2, given in two doses 12 hours apart.
Study: 26960786
Drug: Intramuscular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular therapy of 1 ml Vitamin B12 (2500 mcg) weekly for 6 weeks
Study: 16239177
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment (no identified underlying aetiology)
Study: 11452896
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 25 mg acetylsalicylic acid (ASA)
Study: 10489049
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200 mg dipyridamole (DP)
Study: 10489049
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 50 mg ASA and 400 mg DP
Study: 11212158
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg twice daily
Study: 1924052
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg once daily
Study: 7117676
Drug: Slow-release frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release frusemide (once-daily)
Study: 31731368
Drug: TDF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF (300 mg per day)
Study: 31731368
Drug: ETV +
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETV + ADV (0.5 mg + 10 mg per day)
Study: 27490918
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d soy isoflavones
Study: 22813645
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy with HIV primary care but ART initiated later
Study: 5470432
Drug: oral oestrogen-gestogen
Normalized name: gestodene
DrugBank: Gestodene (DB06730)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral oestrogen-gestogen combination
Study: 17878473
Drug: Investigational drugs
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drugs or devices
Study: 28455597
Drug: Digitalis treatment
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis treatment
Study: 15732025
Drug: Digitalis treatment
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis treatment with propensity analysis
Study: 12074253
Drug: Egg (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg (640 mg additional dietary cholesterol per day)
Study: 2183617
Drug: single-dose cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose cephalosporin antibiotic prophylaxis
Study: 19356621
Drug: FMP2.1/AS02A half-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS02A half-dose (25 microg/0.25 ml)
Study: 24260195
Drug: Control rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control rabies vaccine
Study: 19356621
Drug: FMP2.1/AS02A (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS02A (both doses)
Study: 17644511
Drug: CoQ(10) supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) supplementation (300 mg/day for 1 month)
Study: 12358921
Drug: Cytotoxic consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic consolidation chemotherapy following tandem transplants (TT)
Study: 11275293
Drug: Melatonin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administration
Study: 7772356
Drug: Droperidol 300
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol 300 mcg/kg orally
Study: 29512784
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen gel and oral aspirin combination therapy
Study: 29512784
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen only therapy
Study: 19770778
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy after crossover
Study: 11856388
Drug: Endosseous implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endosseous implant systems (IMZ, Brånemark, Transmandibular)
Study: 11856388
Drug: Endosseous implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endosseous implant systems (IMZ, Brånemark)
Study: 11856388
Drug: Transmandibular Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular Implant system
Study: 10452767
Drug: cetirizine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetirizine 0.25 mg/kg twice daily
Study: 31335572
Drug: Control (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inactivated trivalent influenza vaccine)
Study: 11092517
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous insulin therapy (PIVIT) in addition to intensive therapy (IT)
Study: 1957968
Drug: Flunarizine (FLN)
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (FLN) administered as drops in a single evening dose of 5 mg (patients <10 years) or 10 mg (patients >10 years)
Study: 19813463
Drug: Piroxicam cream
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam cream (1%, applied three times a day)
Study: 18381903
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (15 or 30 mg/day)
Study: 16449030
Drug: Loop diuretics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics, aminoglycosides, neuromuscular blockers (NMB), and vancomycin (50 received vancomycin)